Drugs / TJ271
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05338580 | Dec 2023 | melanoma, non-small cell lung carcinoma, urothelial carcinoma | TJ Biopharma Co., Ltd. | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TJ271 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05338580 ↗ |